Literature DB >> 20926211

Clinical fractures cluster in time after initial fracture.

Tineke A C M Laurs-van Geel1, Jacqueline R Center, Piet P Geusens, Geert-Jan Dinant, John A Eisman.   

Abstract

A history of fractures is a well recognised risk factor for a new clinical fracture. However, this subsequent fracture risk is not constant, but fluctuates over time, with the greatest increase in the years immediately after the initial fracture, followed by a gradual waning of risk toward the population risk. The clustering of fractures occurred regardless of age, gender and initial fracture location. It is therefore likely that fracture risk models, which take into account this fluctuation of fracture risk over time, will be more relevant in predicting an individual's subsequent fracture risk. Regardless of the cause of this clustering, these studies all strongly support the need for early action after an initial fracture to reduce the preventable risk of subsequent fractures with medical interventions that have been shown to immediately decrease the risk of fractures.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20926211     DOI: 10.1016/j.maturitas.2010.09.002

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  4 in total

Review 1.  Models of care for the secondary prevention of osteoporotic fractures: a systematic review and meta-analysis.

Authors:  K Ganda; M Puech; J S Chen; R Speerin; J Bleasel; J R Center; J A Eisman; L March; M J Seibel
Journal:  Osteoporos Int       Date:  2012-07-25       Impact factor: 4.507

2.  Romosozumab efficacy and safety in European patients enrolled in the FRAME trial.

Authors:  Bente Langdahl; Lorenz C Hofbauer; Serge Ferrari; Zhenxun Wang; Astrid Fahrleitner-Pammer; Evelien Gielen; Péter Lakatos; Edward Czerwinski; Esteban Jódar Gimeno; Jen Timoshanko; Mary Oates; Cesar Libanati
Journal:  Osteoporos Int       Date:  2022-09-29       Impact factor: 5.071

3.  Characteristics of patients who suffer major osteoporotic fractures despite adhering to alendronate treatment: a National Prescription registry study.

Authors:  B Abrahamsen; K H Rubin; P A Eiken; R Eastell
Journal:  Osteoporos Int       Date:  2012-10-16       Impact factor: 4.507

4.  Joint position statement on management of patient with osteoporosis during COVID-19 contingency from the AMMOM, CONAMEGER, FELAEN, FEMECOG, FEMECOT, and ICAAFYD.

Authors:  Francisco Torres-Naranjo; Pilar De la Peña-Rodríguez; Roberto Enrique López-Cervantes; Jorge Morales-Torres; Jorge Morales-Vargas; Hugo Gutiérrez-Hermosillo; Alan Christopher Guzmán-Rico; Roberto Gabriel González-Mendoza; Pedro Nel Rueda Plata; Miguel Flores Castro; Cuauhtémoc Celis Gonzalez; Rolando Espinosa Morales; Sergio Quintero Hernández; Juan Ricardo López-Taylor
Journal:  Arch Osteoporos       Date:  2021-01-25       Impact factor: 2.617

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.